USA pharmaceutical company Eli Lilly and Co (LLY.US) has signed a research agreement with AI biotechnology company Genetic Leap to develop gene therapy drugs. Genetic Leap will receive up to $0.409 billion in upfront and milestone payments, as well as royalty fees.

Major pharmaceutical companies have been trying to use AI to develop new drugs, find patients for clinical trials, and reduce the number of participants required for drug testing.